Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X4SI
|
|||
| Former ID |
DPR000102
|
|||
| Drug Name |
RS-504393
|
|||
| Synonyms |
300816-15-3; RS 504393; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; RS-504393; RS504393; CHEMBL134074; 6-Methyl-1'-(2-(5-methyl-2-phenyloxazol-4-yl)ethyl)spiro-[benzo[d][1,3]oxazine-4,4'-piperidin]-2(1H)-one; 6-Methyl-1'-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]spiro[4H-3,1-benzoxazine-4,4'-piperidin]-2(1H)-one; ACMC-20a25e; GTPL781; SCHEMBL9972645; CTK4G4374; CHEBI:93525; DTXSID20433290; MolPort-021-804-998; BCPP000086; HMS3269M19; BCP02713; ZINC13527116; ABP000463
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Preclinical | [1], [2] | |
| Company |
Roche
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H27N3O3
|
|||
| Canonical SMILES |
CC1=CC2=C(C=C1)NC(=O)OC23CCN(CC3)CCC4=C(OC(=N4)C5=CC=CC=C5)C
|
|||
| InChI |
1S/C25H27N3O3/c1-17-8-9-22-20(16-17)25(31-24(29)27-22)11-14-28(15-12-25)13-10-21-18(2)30-23(26-21)19-6-4-3-5-7-19/h3-9,16H,10-15H2,1-2H3,(H,27,29)
|
|||
| InChIKey |
ODNICNWASXKNNQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 300816-15-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14929247, 24696404, 46050378, 50112894, 79972630, 85788710, 103366079, 104024068, 134339542, 135566646, 135650944, 135698770, 136367799, 138230843, 151981512, 152258709, 152344313, 160647545, 160821210, 162023521, 162301649, 162832691, 163374671, 164023446, 172912668, 185964418, 204382744, 208265223, 223384980, 223573234, 235319579, 242059981, 249583053, 249826996, 250208962, 252059307, 252126288, 252156578, 252216233, 252436124
|
|||
| ChEBI ID |
CHEBI:93525
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 781). | |||
| REF 2 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | |||
| REF 3 | Beneficial or detrimental effects of carotenoids contained in food: cell culture models. Mini Rev Med Chem. 2007 Nov;7(11):1120-8. | |||
| REF 4 | Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.